Trastuzumab

Adult: As monotherapy in patients who have received ≥1 chemotherapy regimens, in combination with paclitaxel or docetaxel in patients who have not received chemotherapy, or in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive cases: Weekly schedule: Initially, 4 mg/kg, followed after 1 week by a maintenance dose of 2 mg/kg given at weekly intervals. Alternative dosing recommendation: 3-weekly schedule: Initially, 8 mg/kg, followed after 3 weeks by a maintenance dose of 6 mg/kg once every 3 weeks. Continue until disease progression. Doses are given initially via IV infusion over 90 minutes; if tolerated, subsequent doses may be given via IV infusion over 30 minutes. Missed dose: If missed dose is ≤1 week, give usual maintenance dose (weekly regimen: 2 mg/kg or 3-weekly regimen: 6 mg/kg) as soon as possible; do not wait until the next planned cycle. Subsequent maintenance doses must be given 7 days or 21 days later based on the weekly or 3-weekly schedules, respectively. If missed dose is >1 week, a re-loading dose (weekly regimen: 4 mg/kg or 3-weekly regimen: 8 mg/kg) must be given (over 90 minutes) as soon as possible. Subsequent maintenance doses (weekly regimen: 2 mg/kg or 3-weekly regimen: 6 mg/kg) must be given 7 days or 21 days later based on the weekly or 3-weekly schedules, respectively. Dose interruption or discontinuation may be required according to individual safety or tolerability. Treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).

Adult: In combination with adjuvant chemotherapy (consisting of docetaxel and carboplatin) or neoadjuvant chemotherapy followed by adjuvant trastuzumab for locally advanced breast cancer or tumours >2 cm in diameter; following surgery, chemotherapy (adjuvant or neoadjuvant) and radiotherapy (if applicable); following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel: Weekly schedule: Initially, 4 mg/kg, followed after 1 week by a maintenance dose of 2 mg/kg given at weekly intervals. Alternative dosing recommendation: 3-weekly schedule: Initially, 8 mg/kg, followed after 3 weeks by a maintenance dose of 6 mg/kg once every 3 weeks. Continue treatment for 1 year or until recurrence of disease occurs. Doses are given initially via IV infusion over 90 minutes; if tolerated, subsequent doses may be given via IV infusion over 30 minutes. Missed dose: If missed dose is ≤1 week, give usual maintenance dose (weekly regimen: 2 mg/kg or 3-weekly regimen: 6 mg/kg) as soon as possible; do not wait until the next planned cycle. Subsequent maintenance doses must be given 7 days or 21 days later based on the weekly or 3-weekly schedules, respectively. If missed dose is >1 week, a re-loading dose (weekly regimen: 4 mg/kg or 3-weekly regimen: 8 mg/kg) must be given (over 90 minutes) as soon as possible. Subsequent maintenance doses (weekly regimen: 2 mg/kg or 3-weekly regimen: 6 mg/kg) must be given 7 days or 21 days later based on the weekly or 3-weekly schedules, respectively. Dose interruption or discontinuation may be required according to individual safety or tolerability. Treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).

Adult: In combination with 5-fluorouracil or capecitabine and cisplatin for patients who have not received prior anti-cancer therapy: 3-weekly schedule: Initially, 8 mg/kg, followed after 3 weeks by a maintenance dose of 6 mg/kg once every 3 weeks. Continue until disease progression. Doses are given initially via IV infusion over 90 minutes; if tolerated, subsequent doses may be given via IV infusion over 30 minutes. Missed dose: If missed dose is ≤1 week, give the usual maintenance dose (3-weekly schedule: 6 mg/kg) as soon as possible; do not wait until the next planned cycle. Subsequent maintenance doses must be given 21 days later based on the 3-weekly schedule. If missed dose is >1 week, a re-loading dose (3-weekly regimen: 8 mg/kg) must be given (over 90 minutes) as soon as possible. Subsequent maintenance doses (3-weekly regimen: 6 mg/kg) must be given 21 days later based on the 3-weekly schedule. Dose interruption or discontinuation may be required according to individual safety or tolerability. Treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).

Adult: In combination with adjuvant chemotherapy (consisting of docetaxel and carboplatin) or neoadjuvant chemotherapy followed by adjuvant trastuzumab for locally advanced breast cancer or tumours >2 cm in diameter; following surgery, chemotherapy (adjuvant or neoadjuvant) and radiotherapy (if applicable); following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel: 600 mg once every 3 weeks via SC inj over 2-5 minutes. Continue treatment for 1 year or until disease recurrence. Missed dose: Administer the missed dose as soon as possible; interval between consecutive doses must not be <3 weeks. Dose interruption or discontinuation may be required according to individual safety or tolerability. Treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).

Adult: As monotherapy in patients who have received ≥1 chemotherapy regimens, in combination with paclitaxel or docetaxel in patients who have not received chemotherapy, or in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive cases not previously treated with trastuzumab: 600 mg once every 3 weeks via SC inj over 2-5 minutes. Continue until disease progression. Missed dose: Administer the missed dose as soon as possible; interval between consecutive doses must not be <3 weeks. Dose interruption or discontinuation may be required according to individual safety or tolerability. Treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).